scholarly journals Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications

2021 ◽  
Vol 11 (15) ◽  
pp. 6930
Author(s):  
Martina Caruso ◽  
Valeria Romeo ◽  
Arnaldo Stanzione ◽  
Carlo Buonerba ◽  
Giuseppe Di Lorenzo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Response ◽  
Antiangiogenic Agents ◽  
Imaging Evaluation ◽  
Medical Treatments ◽  
Metastatic Rcc

The present review is focused on the role of diagnostic tomographic imaging such as computed tomography and magnetic resonance imaging to assess and predict tumor response to advanced medical treatments in metastatic renal cell carcinoma (RCC) patients. In this regard, antiangiogenic agents and immune checkpoint inhibitors (ICIs) have developed as advanced treatment options replacing the conventional therapy based on interferon-alpha and interleuchin-2 which had unfavorable toxicity profile and low response rates. In clinical practice, the imaging evaluation of treatment response in cancer patients is based on dimensional changes of tumor lesions in sequential scans; in particular, Response Evaluation Criteria in Solid Tumors (RECIST) have been defined for this purpose and also applied in patients with metastatic RCC. However, these new drugs with predominant cytostatic effect make RECIST insufficient to realize an adequate response imaging evaluation. Therefore, new imaging criteria (mCHOI and iRECIST) have been proposed to assess tumor response to advanced medical treatments of metastatic RCC, they correlate better than RECIST with the progression-free survival and overall survival. Finally, a potential role of radiomics and machine learning models has been suggested to predict tumor response.

scholarly journals Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

2021 ◽  
Vol 47 (Supp1) ◽  
pp. S79-S84
Author(s):  
Charles Van Praet ◽  
◽  
Charlotte Slots ◽  
Nikhil Vasdev ◽  
Sylvie Rottey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cytoreductive Nephrectomy ◽  
Current Role

Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma

2013 ◽  
Vol 62 (12) ◽  
pp. 1757-1768 ◽  
Author(s):  
Matteo Santoni ◽  
Francesco Massari ◽  
Consuelo Amantini ◽  
Massimo Nabissi ◽  
Francesca Maines ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Targets ◽  
Tumor Associated Macrophages

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

2011 ◽  
Vol 9 (9) ◽  
pp. 985-993 ◽  
Author(s):  
Robert Torrey ◽  
Philippe E. Spiess ◽  
Sumanta K. Pal ◽  
David Josephson
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Locally Advanced ◽  
Disease Stage ◽  
Disease Characteristics ◽  
Multimodal Management

Both locally advanced and metastatic renal cell carcinoma (RCC) present a challenge in terms of their optimal management. This article reviews the literature and evaluates the role of surgery in the treatment of advanced RCC. Surgery is the optimal treatment for locally advanced RCC and minimal, resectable, metastatic disease. Patients with metastatic disease, and some forms of locally advanced disease, may also benefit from multimodal management with local surgical therapy and systemic treatment using either immunotherapy or targeted therapy. Regardless of the disease stage, patients with locally advanced or metastatic RCC represent heterogenous patient populations with different disease characteristics and risk factors. Individualization of care in the setting of a sound oncologic framework may optimize the risk/benefit ratio within individual patient cohorts.

Sign in / Sign up

Export Citation Format

Share Document